Head-to-head evidence
semaglutide vs TTP273
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline
semaglutide · Wegovy / Ozempic / Rybelsus
Marketed by Novo Nordisk
NCT01720446 · Phase 3 · completed
This was a large randomized, double-blind, placebo-controlled trial with 1,648 participants receiving semaglutide and 1,649 receiving placebo. The hard clinical primary endpoint, first major adverse cardiovascular event, occurred in 6.6% versus 8.9% of participants; the prespecified non-inferiority comparison was met (hazard ratio 0.74, 95% CI 0.58–0.95, p<0.0001), and a post hoc superiority analysis was statistically significant (p=0.0167).
Next expected readout: November 2026 · NCT07570810 (registry estimate)
TTP273
Developed by vTv Therapeutics
NCT02653599 · Phase 2 · completed
In this randomized, double-blind, placebo-controlled trial of 174 participants, TTP273 lowered HbA1c by a statistically significant margin relative to placebo at both once-daily and twice-daily dosing, while HbA1c rose slightly in the placebo group.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: semaglutide's landscape · TTP273's landscape